Trial intelligence / Profile preview

Panitumumab with Chemoradiation for Esophageal Cancer

NCT00578071Phase 2

Key facts

Status: Completed
Start: Dec 2007
Primary completion: Jul 2011
Countries: 1
Modality: Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies

Drugs: panitumumab
Conditions: esophageal carcinoma

Overview

Phase 2, open-label, single-arm trial of panitumumab in esophageal carcinoma. Primary endpoints: Panitumumab Maximum Tolerated Dose at 60 days and Number of Participants With Dose-limiting Toxicities. Started Dec 2007; status: completed.

Design

1 arm

Study design: Non-randomizedOpen-label

Panitumumab + Chemoradiation
Panitumumab + Capecitabine + Oxaliplatin + External Beam Radiation Therapy

Endpoints

Primary

Panitumumab Maximum Tolerated Dose60 days
Number of Participants With Dose-limiting ToxicitiesWithin 30 days of the last day of radiation

Secondary

Overall Survival Rates1 year
Pathological Complete Response Rates90 days

Beyond the preview

Go deeper on NCT00578071.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00578071.